Short Interest in Tema Oncology ETF (NASDAQ:CANC) Rises By 283.3%

Tema Oncology ETF (NASDAQ:CANC) was the target of a large growth in short interest during the month of September. As of September 30th, there was short interest totalling 2,300 shares, a growth of 283.3% from the September 15th total of 600 shares. Based on an average daily volume of 5,000 shares, the short-interest ratio is currently 0.5 days.

Tema Oncology ETF Price Performance

Shares of CANC stock traded up $0.60 during trading hours on Friday, hitting $28.48. The stock had a trading volume of 3,074 shares, compared to its average volume of 7,297. The stock has a market capitalization of $49.56 million, a price-to-earnings ratio of 26.86 and a beta of 1.11. Tema Oncology ETF has a one year low of $21.26 and a one year high of $30.11. The stock’s 50-day moving average price is $28.70 and its two-hundred day moving average price is $27.88.

Institutional Trading of Tema Oncology ETF

An institutional investor recently bought a new position in Tema Oncology ETF stock. Thrivent Financial for Lutherans bought a new stake in shares of Tema Oncology ETF (NASDAQ:CANC) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 319,376 shares of the company’s stock, valued at approximately $8,616,000. Thrivent Financial for Lutherans owned approximately 19.01% of Tema Oncology ETF at the end of the most recent quarter.

Tema Oncology ETF Company Profile

The Tema Oncology ETF (CANC) is an exchange-traded fund that mostly invests in health care equity. The fund is actively managed, investing in stocks of companies focused on cancer treatment and management from issuers all around the world. The fund uses a bottom-up approach to select pioneering companies at perceived attractive valuations CANC was launched on Aug 15, 2023 and is issued by Tema.